Shield Therapeutics PLC (STX)

Industry Drug Manufacturers - Specialty & Generic


This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

9.00p

Buy

9.30p

arrow-up0.05p (+0.54%)

Prices updated at 23 Apr 2026, 15:18 BST
| Prices minimum 15 mins delay
|
Prices in GBX

Shield Therapeutics PLC is focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. It is a specialty pharmaceutical company.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Mr. Hans Peter Hasler
CEO
Mr. Karl Anders Lundstrom
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
63
Head office
Northern Design Centre
Newcastle
United Kingdom
NE8 3DF
mobile
+44 1915118500
letter
investorrelations@shieldtx.com

Key personnel

Salary
Mr. Peter Hermann William Llewellyn-Davies
Non-Executive Director, Vice Chairman
-
Mr. Hans Peter Hasler
Non-Executive Director, Chairman
-
Ms. Maria Fabiana Lacerca-Allen
Non-Executive Director
-
Dr. Christian Schweiger
Non-Executive Director
-
Mr. Karl Anders Lundstrom
Executive Director, Chief Executive Officer
-

Top 5 shareholders

No. of shares
Miton Asset Management Limited5,725,916
Premier Miton UK Smaller Companies5,725,916
Mandarine Gestion5,030,000
Mandarine Europe Microcap4,500,000
IFSL Marlborough Nano Cap Growth Fund1,250,000

Director dealings

Action
No data
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.